NCT07131254View on ClinicalTrials.gov

GT719 Injection for CD19 Positive Recurrent/Refractory Adult B-cell Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

September 24, 2027

Study Completion Date

September 24, 2027

Conditions

Hematological Malignancy (Leukemia- Lymphoma)

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Trial Locations (1)

Unknown

RECRUITING

Ganzhou City People's Hospital, Ganzhou

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

collaborator

Ganzhou City People's Hospital

OTHER

lead

Grit Biotechnology

INDUSTRY

NCT07131254 - GT719 Injection for CD19 Positive Recurrent/Refractory Adult B-cell Malignancies | Biotech Hunter | Biotech Hunter